Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment. Georghiou, S. B., Rodwell, T. C., Korobitsyn, A., Abbadi, S. H., Ajbani, K., Alffenaar, J., Alland, D., Alvarez, N., Andres, S., Ardizzoni, E., Aubry, A., Baldan, R., Ballif, M., Barilar, I., Böttger, E. C., Chakravorty, S., Claxton, P. M., Cirillo, D. M., Comas, I., Coulter, C., Denkinger, C. M., Derendinger, B., Desmond, E. P., de Steenwinkel, J. E., Dheda, K., Diacon, A. H., Dolinger, D. L., Dooley, K. E., Egger, M., Ehsani, S., Farhat, M. R., Fattorini, L., Finci, I., Le Ray, L. F., Furió, V., Groenheit, R., Gumbo, T., Heysell, S. K., Hillemann, D., Hoffmann, H., Hsueh, P., Hu, Y., Huang, H., Hussain, A., Ismail, F., Izumi, K., Jagielski, T., Johnson, J. L., Kambli, P., Kaniga, K., Eranga Karunaratne, G., Sharma, M. K., Keller, P. M., Kelly, E. C., Kholina, M., Kohli, M., Kranzer, K., Laurenson, I. F., Limberis, J., Grace Lin, S., Liu, Y., López-Gavín, A., Lyander, A., Machado, D., Martinez, E., Masood, F., Mitarai, S., Mvelase, N. R., Niemann, S., Nikolayevskyy, V., Maurer, F. P., Merker, M., Miotto, P., Omar, S. V., Otto-Knapp, R., Palaci, M., Palacios Gutiérrez, J. J., Peacock, S. J., Peloquin, C. A., Perera, J., Pierre-Audigier, C., Pholwat, S., Posey, J. E., Prammananan, T., Rigouts, L., Robledo, J., Rockwood, N., Rodrigues, C., Salfinger, M., Schechter, M. C., Seifert, M., Sengstake, S., Shinnick, T., Shubladze, N., Sintchenko, V., Sirgel, F., Somasundaram, S., Sterling, T. R., Spitaleri, A., Streicher, E., Supply, P., Svensson, E., Tagliani, E., Tahseen, S., Takaki, A., Theron, G., Torrea, G., Van Deun, A., van Ingen, J., Van Rie, A., van Soolingen, D., Vargas Jr, R., Venter, A., Veziris, N., Villellas, C., Viveiros, M., Warren, R., Wen, S., Werngren, J., Wilkinson, R. J., Yang, C., Yılmaz, F. F., Zhang, T., Zimenkov, D., Ismail, N., Köser, C. U., & Schön, T. European Respiratory Journal, 59(4):2200166, European Respiratory Society, apr, 2022.
Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment [link]Paper  doi  abstract   bibtex   
Approximately 85 000 deaths globally in 2019 were due to drug-resistant tuberculosis (TB), which corresponds to 7% of global deaths attributable to bacterial antimicrobial resistance [1]. Yet concerns have been mounting that drug-resistant TB was being underestimated because the approaches to define susceptibility and resistance to anti-TB agents had not kept up with those used for other major bacterial pathogens [2–9]. Here, we outline the recent, evidence-based initiatives spearheaded by the World Health Organization (WHO) and others to update breakpoints (traditionally referred to as critical concentrations (CCs)) that are used for phenotypic antimicrobial susceptibility testing (AST), also called drug susceptibility testing in the TB literature. Inappropriately high breakpoints have resulted in systematic false-susceptible AST results to anti-TB drugs. MIC, PK/PD and clinical outcome data should be combined when setting breakpoints to minimise the emergence and spread of antimicrobial resistance. \textlesshttps://bit.ly/3i43wb6\textgreater We thank Andrew Vernon and others who are acknowledged in the respective WHO reports covered in this viewpoint for sharing relevant data.
@article{AntimycobacterialSusceptibilityTestingGroup2022,
abstract = {Approximately 85 000 deaths globally in 2019 were due to drug-resistant tuberculosis (TB), which corresponds to 7{\%} of global deaths attributable to bacterial antimicrobial resistance [1]. Yet concerns have been mounting that drug-resistant TB was being underestimated because the approaches to define susceptibility and resistance to anti-TB agents had not kept up with those used for other major bacterial pathogens [2–9]. Here, we outline the recent, evidence-based initiatives spearheaded by the World Health Organization (WHO) and others to update breakpoints (traditionally referred to as critical concentrations (CCs)) that are used for phenotypic antimicrobial susceptibility testing (AST), also called drug susceptibility testing in the TB literature. Inappropriately high breakpoints have resulted in systematic false-susceptible AST results to anti-TB drugs. MIC, PK/PD and clinical outcome data should be combined when setting breakpoints to minimise the emergence and spread of antimicrobial resistance. {\textless}https://bit.ly/3i43wb6{\textgreater} We thank Andrew Vernon and others who are acknowledged in the respective WHO reports covered in this viewpoint for sharing relevant data.},
author = {Georghiou, Sophia B. and Rodwell, Timothy C. and Korobitsyn, Alexei and Abbadi, Said H. and Ajbani, Kanchan and Alffenaar, Jan-Willem and Alland, David and Alvarez, Nataly and Andres, S{\"{o}}nke and Ardizzoni, Elisa and Aubry, Alexandra and Baldan, Rossella and Ballif, Marie and Barilar, Ivan and B{\"{o}}ttger, Erik C. and Chakravorty, Soumitesh and Claxton, Pauline M. and Cirillo, Daniela M. and Comas, I{\~{n}}aki and Coulter, Chris and Denkinger, Claudia M. and Derendinger, Brigitta and Desmond, Edward P. and de Steenwinkel, Jurriaan E.M. and Dheda, Keertan and Diacon, Andreas H. and Dolinger, David L. and Dooley, Kelly E. and Egger, Matthias and Ehsani, Soudeh and Farhat, Maha R. and Fattorini, Lanfranco and Finci, Iris and {Le Ray}, Laure Fournier and Furi{\'{o}}, Victoria and Groenheit, Ramona and Gumbo, Tawanda and Heysell, Scott K. and Hillemann, Doris and Hoffmann, Harald and Hsueh, Po-Ren and Hu, Yi and Huang, Hairong and Hussain, Alamdar and Ismail, Farzana and Izumi, Kiyohiko and Jagielski, Tomasz and Johnson, John L. and Kambli, Priti and Kaniga, Kon{\'{e}} and {Eranga Karunaratne}, G.H.R. and Sharma, Meenu Kaushal and Keller, Peter M. and Kelly, Ellis C. and Kholina, Margarita and Kohli, Mikashmi and Kranzer, Katharina and Laurenson, Ian F. and Limberis, Jason and {Grace Lin}, S-Y. and Liu, Yongge and L{\'{o}}pez-Gav{\'{i}}n, Alexandre and Lyander, Anna and Machado, Diana and Martinez, Elena and Masood, Faisal and Mitarai, Satoshi and Mvelase, Nomonde R. and Niemann, Stefan and Nikolayevskyy, Vladyslav and Maurer, Florian P. and Merker, Matthias and Miotto, Paolo and Omar, Shaheed V. and Otto-Knapp, Ralf and Palaci, Mois{\'{e}}s and {Palacios Guti{\'{e}}rrez}, Juan Jos{\'{e}} and Peacock, Sharon J. and Peloquin, Charles A. and Perera, Jennifer and Pierre-Audigier, Catherine and Pholwat, Suporn and Posey, James E. and Prammananan, Therdsak and Rigouts, Leen and Robledo, Jaime and Rockwood, Neesha and Rodrigues, Camilla and Salfinger, Max and Schechter, Marcos C. and Seifert, Marva and Sengstake, Sarah and Shinnick, Thomas and Shubladze, Natalia and Sintchenko, Vitali and Sirgel, Frederick and Somasundaram, Sulochana and Sterling, Timothy R. and Spitaleri, Andrea and Streicher, Elizabeth and Supply, Philip and Svensson, Erik and Tagliani, Elisa and Tahseen, Sabira and Takaki, Akiko and Theron, Grant and Torrea, Gabriela and {Van Deun}, Armand and van Ingen, Jakko and {Van Rie}, Annelies and van Soolingen, Dick and {Vargas Jr}, Roger and Venter, Amour and Veziris, Nicolas and Villellas, Cristina and Viveiros, Miguel and Warren, Robin and Wen, Shu'an and Werngren, Jim and Wilkinson, Robert J. and Yang, Caie and Yılmaz, F. Ferda and Zhang, Tingting and Zimenkov, Danila and Ismail, Nazir and K{\"{o}}ser, Claudio U. and Sch{\"{o}}n, Thomas},
doi = {10.1183/13993003.00166-2022},
file = {:C$\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Antimycobacterial Susceptibility Testing Group - 2022 - Updating the approaches to define susceptibility and resistance to anti-tubercul.pdf:pdf;:C$\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Group et al. - 2022 - Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents implications for diagn.pdf:pdf},
issn = {0903-1936},
journal = {European Respiratory Journal},
keywords = {OA,editorial,fund{\_}ack},
mendeley-tags = {OA,editorial,fund{\_}ack},
month = {apr},
number = {4},
pages = {2200166},
pmid = {35422426},
publisher = {European Respiratory Society},
title = {{Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment}},
url = {https://erj.ersjournals.com/content/59/4/2200166 https://erj.ersjournals.com/content/59/4/2200166.abstract http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00166-2022},
volume = {59},
year = {2022}
}

Downloads: 0